What Happened?
Shares of healthcare solutions company Evolent Health (NYSE: EVH) fell 13% in the afternoon session after Wall Street firm Citi downgraded the company's stock from Buy to Neutral. Despite raising the price target from $5.50 to $6.75, the investment firm reassessed the stock's potential, citing a less attractive risk-to-reward setup following a recent price increase. Analysts highlighted uncertainties surrounding healthcare exchange dis-enrollment and shifts in patient care needs. Additionally, Citi placed Evolent Health on a 30-day "downside catalyst watch." The firm expressed doubt about the company's ability to meet the upper end of its financial guidance due to rising medical costs.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Evolent Health? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Evolent Health’s shares are extremely volatile and have had 57 moves greater than 5% over the last year. But moves this big are rare even for Evolent Health and indicate this news significantly impacted the market’s perception of the business.
The biggest move we wrote about over the last year was 5 months ago when the stock gained 20.7% on the news that the company reported fourth-quarter earnings that beat expectations and provided an optimistic revenue forecast for the upcoming year. The healthcare solutions company announced non-GAAP earnings of $0.08 per share, a significant improvement from the $0.02 per share loss recorded in the same quarter a year earlier and well ahead of analyst forecasts. While quarterly revenue fell 27.5% year-over-year to $468.7 million, this figure met Wall Street's expectations. Investors appeared to focus on the company's strong future guidance. Evolent projected its revenue for the full year 2026 to be between $2.4 billion and $2.6 billion. The midpoint of this range suggested growth of approximately 30% and was nearly 5% above analysts' estimates. The positive outlook seemed to overshadow the company’s lower-than-expected guidance for adjusted EBITDA.
Evolent Health is up 23.5% since the beginning of the year, but at $4.81 per share, it is still trading 52.9% below its 52-week high of $10.21 from July 2025. Despite the year-to-date gain, investors who bought $1,000 worth of Evolent Health’s shares 5 years ago would now be looking at only $220.01.
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.
